中國生物科技服務(08037.HK)擬先舊後新配發1250萬股 總籌500萬港元
格隆匯7月21日丨中國生物科技服務(08037.HK)發佈公吿,2024年7月20日,Genius Lead訂立配售協議,據此,Genius Lead同意出售1250萬股股份予承配人(即Ming Fu先生),有關價格為每股配售股份0.40港元。同日,Genius Lead與公司訂立先舊後新認購協議。根據先舊後新認購協議,公司有條件同意配發及發行而Genius Lead有條件同意認購1250萬股股份(相當於配售協議下Genius Lead出售配售股份的數目),價格為每股先舊後新認購股份0.40港元。
合共1250萬股配售股份(或先舊後新認購項下將予配發及發行的先舊後新認購股份)佔公司於本公吿日期已發行股本約1.30%;及經根據先舊後新認購協議配發及發行先舊後新認購股份擴大的已發行股本約1.28%。配售為無條件且配售將於2024年7月24日完成。
先舊後新認購股份將根據一般授權予以配發及發行。先舊後新認購所得款項總額總計將約為500萬港元,估計先舊後新認購所得款項淨額總計約為460萬港元,相當於每股先舊後新認購股份淨髮行價約為0.368港元。現擬將先舊後新認購所得款項淨額用作一般營運資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.